USPTO serial 99005505
CANAVERAL
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- OSBORNE, AUDRIANA R
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CANAVERAL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kristin H. Altoff
Kristin H. Altoff Morgan Lewis & Bockius LLP1111 Pennsylvania Avenue, NWWashington, DC 20004-2541United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations, namely, nucleic acids, proteins, and peptides for medical and veterinary purposes; Chemical and biological diagnostic preparations and substances, namely, nucleic acids, proteins and polypeptides, small molecules for medical or veterinary purposes in clinical and medical laboratory use in drug discovery and nucleic acid and protein therapeutics in the bio-pharmaceutical industry; Nucleic acid-protein conjugates for medical or veterinary purposes; Nucleic acids for medical purposes; Nucleic acid therapeutic pharmaceuticals for the treatment of extra-hepatic disease; nucleic acid and protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceutical preparations, namely, nucleic acid and protein therapeutics for the treatment of a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceuticals using protein biotherapeutics to treat a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceutical preparations containing nucleic acid and protein therapeutics for the treatment of immune system, infectious disease, pulmonary diseases and disorders, genetic diseases, metabolic diseases, kidney diseases, reproductive disorders, gastrointestinal diseases, cancers, and obesity; Protein therapeutic pharmaceuticals for the treatment of human conditions, namely a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases. | ACTIVE | — |
| 042 | Biotechnology, medical and scientific research, and development services in the field of nucleic acid and protein therapeutics and diagnostics; Biotechnology research services, namely, nucleic acid and protein therapeutics development for applications in the lung, pediatric, gastrointestinal, reproductive, kidney, metabolic, infectious disease, cancer, immunological, and genetic disciplines; Medical and scientific research and development services in the field of nucleic acid and protein therapeutics and diagnostics; Research and development of medicines; Pharmaceutical research and development services in the field of nucleic acid and protein therapeutics. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 11, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 11, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 11, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 27, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 2, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 2, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 26, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 1, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 31, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 31, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 31, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 19, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 17, 2025 | NWAP | NEW APPLICATION ENTERED | — |